Rutgers, The State University of New Jersey
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Rutgers, The State University of New Jersey sits in the top decile of US sponsors by registered trial count (#86 of 15,742 sponsors by registered trial count).
Rutgers, The State University of New Jersey: 413 sponsored US clinical trials, 109 recruiting.
Rutgers, The State University of New Jersey sponsors 413 registered US clinical trials on ClinicalTrials.gov, 109 of them currently recruiting, and 196 completed. 35 of these trials are in Phase 3-4 (later-stage) and 104 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Autism Spectrum Disorder, with 6 trials.
Top-decile sponsor footprint
Rutgers, The State University of New Jersey ranks in the top decile of sponsors by registered trial count (#86 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
196 of 267 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (73.4%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
413 total, page 8 of 9
IV Ibuprofen for Post-Electroconvulsive Therapy Myalgia
NCT01200069
Psychological Interventions for Gynecologic Cancer
NCT01951807
Barriers to Mental Healthcare Utilization in Parkinson's Disease
NCT01167608
Experimentally Testing the Effectiveness of a Campus-based Bystander Intervention
NCT02083302
Facilitating Parent Adaptation to Pediatric Transplant: The P-SCIP Trial
NCT00939380
Pediatric Temperature Variation in the MRI Scanner Under General Anesthesia
NCT01119248
Dialectical Behavior Therapy Rutgers University Research Program
NCT03123198
Lactobacillus in Preventing Infection in Patients Undergoing a Donor Stem Cell Transplant for Hematologic Cancer or Myelodysplastic Syndrome
NCT00946283
The Effects of Hydrocortisone in Endotoxemia in Normal Volunteers
NCT01064986
Isoflurane Preconditioning for Liver Resections
NCT01031550
Health Behaviors in Patients Who Have Finished Treatment for Stage I, Stage II, or Stage III Colorectal Cancer
NCT00966667
Riluzole and Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases
NCT01018836
Dexmedetomidine Versus Propofol in Vitreoretinal Surgery
NCT01001429
Myocardial Ischemia and Transfusion Pilot
NCT01167582
Transfusion Requirements During Spinal Surgery for Severe Scoliosis
NCT01490164
Trial of Nicotine Nasal Spray as an Aid for Smoking Cessation in Schizophrenia
NCT01010477
Phase I/II Study of Weekly Abraxane and RAD001 in Women With Locally Adv. or Metastatic Breast Ca
NCT00934895
Sorafenib Tosylate Before and After Hepatic Arterial Chemoembolization With Doxorubicin Hydrochloride and Mitomycin C in Treating Patients With Localized Liver Cancer That Cannot Be Removed by Surgery
NCT00949182
Vitamin E Supplements in Treating Patients Undergoing Surgery for Colorectal Cancer
NCT00905918
Hydroxychloroquine, Capecitabine, Oxaliplatin, and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
NCT01006369
Measurement of Pro-angiogenic Markers in Patients With Hepatic Metastases Undergoing SIRT
NCT00994370
Riluzole in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery
NCT00866840
Intensity-Modulated Radiation Therapy and Gemcitabine in Treating Patients With Locally Advanced Pancreatic Cancer
NCT00878657
Comparison of Enteral Versus Parenteral Feeding in Healthy Human Subjects
NCT00856219
Atorvastatin Calcium and Celecoxib in Treating Patients With Rising PSA Levels After Local Therapy for Prostate Cancer
NCT01220973
Sunitinib and Irradiated Donor Lymphocytes in Treating Patients With Metastatic Kidney Cancer
NCT00853125
Treatment Decision Making Between Oncologists and Women With Newly Diagnosed Breast Cancer and Their Healthy Companions
NCT00891969
Choline Magnesium Trisalicylate and Combination Chemotherapy in Treating Patients With Acute Myeloid Leukemia
NCT02144675
Collecting and Storing Blood and Tumor Tissue Samples From Patients Undergoing Prostatectomy or Transurethral Resection of the Prostate
NCT00991315
Phase I/II Trial of Letrozole and Sorafenib in Post-Menopausal Hormone-Receptor + Breast Cancer
NCT00634634
Hydroxychloroquine in Treating Patients With Rising PSA Levels After Local Therapy for Prostate Cancer
NCT00726596
Propofol Concentration In The Ambient Air Of The Operating Room And In The Blood Of Anesthesia Care Providers
NCT00695799
Phase II Trial of Doxil, Carboplatin, Bevacizumab in Triple Negative Untreated Metastatic Breast Cancer
NCT00608972
RCT of Effects of Device-guided Breathing on Ambulatory BP
NCT01184755
Determine the Effect of Intraocular Pressure (IOP), Optic Nerve Imaging, Venous Congestion in Volunteers Prone Position 5 Hours
NCT00875043
Study of High Dose Vitamin C On Outcome in Cardiac Surgery Patients
NCT01167569
Licorice Root Extract and Docetaxel in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Hormone Therapy
NCT00176631
Effects of Sevoflurane and Propofol on Light Flashed Evoked Pupillometry
NCT01219569
Capecitabine (Xeloda) and Lapatinib (Tykerb) as First-line Therapy in HER2/Neu-positive Breast Cancer
NCT00496366
Coping With Depression in Parkinson's Disease
NCT00464464
Modulation of Plasmacytoid Dendritic Cell Function in Multiple Sclerosis
NCT00468182
Correlation BIS Scores Mentally Retarded Patients
NCT00468338
A Phase I/II Trial of 2-Deoxyglucose (2DG) for the Treatment of Advanced Cancer and Hormone Refractory Prostate Cancer
NCT00633087
Medical Nutrition Therapy or Standard Care in Treating Patients With Lung Cancer, Pancreatic Cancer, or Stage III or Stage IV Prostate Cancer
NCT00769652
Effects of Nitrous Oxide on Intraocular Pressure
NCT00696189
Gemcitabine +/- Imatinib Mesylate, Patients w/Previously Treated Metastatic Breast Cancer
NCT00323063
Enhancing Motivation To Quit Smoking In Smokers With Serious Mental Illness
NCT00500695
Gemcitabine and Imatinib Mesylate in Treating Patients With Recurrent or Metastatic Non-Small Cell Lung Cancer
NCT00323362
The Use of Capnography as a Guide for Oral Intubation
NCT00176683
Phase II Metronomic Dosing, Etoposide, Cyclophosphamide, D0 Prostate Cancer
NCT00176605
What is open in the Rutgers, The State University of New Jersey pipeline
109 recruiting of 413 indexed (26% open); 196 completed (47%).
Phase mix: 35 late (III/IV) vs 104 early (I/II) (early-phase heavy).
Top condition: Autism Spectrum Disorder (6 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Rutgers, The State University of New Jersey: open-pipeline peers nationwide
Peers matched on 413 registered trials and 26% open enrollment, not the therapeutic-area sidebar.
Rutgers, The State University of New Jersey sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 413 trials (± recruiting share)
- St. Jude Children's Research Hospital · 410 trials · 22% recruiting
- Takeda · 408 trials · 12% recruiting
- University of Kansas Medical Center · 408 trials · 23% recruiting
- Case Comprehensive Cancer Center · 407 trials · 14% recruiting
Sponsors near 26% open enrollment (± trial volume)
- Coherus Oncology · 27% recruiting · 15 trials
- NewAmsterdam Pharma · 27% recruiting · 15 trials
- Portland VA Medical Center · 27% recruiting · 15 trials
- White River Junction Veterans Affairs Medical Center · 27% recruiting · 15 trials
Related
What to do with this Rutgers, The State University of New Jersey page
413 registered trials is a research-attention snapshot, not an endorsement of Rutgers, The State University of New Jersey or any single study.
- 109 of Rutgers, The State University of New Jersey's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Autism Spectrum Disorder is the condition Rutgers, The State University of New Jersey studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Autism Spectrum Disorder trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Rutgers, The State University of New Jersey pipeline card: 413 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.